CJC-1295 and ipamorelin engage discrete receptor populations on the anterior pituitary somatotroph yet converge on overlapping second-messenger cascades, producing a GH secretory response that exceeds either compound administered alone.
GHRH-R and GHS-R1a as separate entry points
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH1-29) incorporating a C-terminal Lys30 with a maleimide-PEG linker that enables covalent albumin binding via Drug Affinity Complex (DAC) technology. This modification extends plasma half-life from approximately 7 minutes (native GHRH) to 6–8 days in rodent models and 5–7 days in human pharmacokinetic studies, without altering the N-terminal tyrosine residue critical for GHRH receptor (GHRH-R) activation. GHRH-R is a Class B1 G protein-coupled receptor (GPCR) coupled primarily through Gs. Ligand binding displaces the receptor from an inactive conformation, enabling Gs α-subunit interaction with adenylyl cyclase III/VI isoforms on the somatotroph plasma membrane.
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide GH secretagogue with high selectivity for GHS-R1a (growth hormone secretagogue receptor 1a), a Gq/11-coupled GPCR. Its selectivity profile differentiates it from earlier GH secretagogues: in vitro receptor binding assays show Ki values of approximately 1–3 nM at GHS-R1a with negligible affinity for GRPR, MC3R, or cortisol-releasing pathways, which explains its minimal effect on ACTH and cortisol secretion versus ghrelin or GHRP-6 in rodent studies (n=12, p<0.01 vs GHRP-6 for ACTH AUC0–120min).
cAMP, PKA and CREB signalling
GHRH-R activation through CJC-1295 elevates intracellular cAMP, activating protein kinase A (PKA). PKA phosphorylates CREB (cAMP response element-binding protein) at Ser133, driving transcription of Gh1 and Pit1 promoter elements. This genomic arm augments somatotroph GH stores over sustained exposure. The rapid secretory arm operates through PKA-mediated phosphorylation of voltage-dependent calcium channel (VDCC) regulatory subunits, facilitating Ca²⁺ influx and SNARE-dependent vesicle exocytosis.
GHS-R1a activation by ipamorelin couples to Gq/11, stimulating phospholipase C-β (PLCβ) to generate IP₃ and diacylglycerol (DAG). IP₃-mediated Ca²⁺ release from the endoplasmic reticulum, combined with DAG activation of protein kinase C (PKC), provides an independent calcium mobilization signal. The functional result is that cAMP-dependent and IP₃-dependent Ca²⁺ signals summate at the level of secretory granule fusion, producing GH pulse amplitudes demonstrably larger than either pathway alone.
Somatostatin tone
Endogenous somatostatin, released from hypothalamic periventricular neurons and from δ-cells in the pancreas, inhibits GH secretion through SSTR1-5 (somatostatin receptor subtypes 1–5). SSTR2 and SSTR5 predominate on the anterior pituitary somatotroph and couple through Gi/o, suppressing adenylyl cyclase activity and thus reducing cAMP levels. SSTR2 additionally activates inwardly rectifying K⁺ channels (GIRK channels), hyperpolarizing the somatotroph membrane and reducing VDCC-mediated Ca²⁺ entry.
CJC-1295 and ipamorelin do not directly antagonize SSTR2 or SSTR5, yet the dual-pathway stimulation appears to partially override somatostatin inhibitory tone through sheer signal amplitude. Ipamorelin additionally exhibits a functional antagonism of somatostatin tone at the hypothalamic level via GHS-R1a-mediated suppression of somatostatin neuron firing, an effect not shared by GHRH analogues.
Pharmacokinetics of each
CJC-1295 with DAC exhibits a terminal half-life (t½β) of approximately 144–192 hours in humans following subcutaneous administration, with bioavailability estimates of 70–80% in rodent subcutaneous models. Peak plasma concentration (Cmax) is reached at 2–4 hours post-injection. Clearance is primarily proteolytic after albumin dissociation; renal filtration plays a minor role given the molecular weight of the albumin-bound complex (~69 kDa).
Ipamorelin has a plasma t½ of approximately 2 hours in rodents and an estimated 2–3 hours in humans based on GH pulse duration data. Its short half-life produces discrete, physiologically-shaped GH pulses rather than sustained elevation, a property considered mechanistically relevant in models studying GH receptor (GHR) downregulation avoidance. Subcutaneous bioavailability is approximately 60–70% in rat models. At the research specification level, both compounds require HPLC purity >99%, acetate salt form, and endotoxin <1 EU/mg to ensure data reproducibility across lots.
Rodent models and lot documentation
The CJC-1295/ipamorelin pairing has been employed in rodent models examining GH-dependent IGF-1 hepatic synthesis, skeletal muscle protein turnover via IGF-1R/IRS-1/PI3K/Akt/mTOR signaling, and adipose tissue lipolysis through GH-mediated HSL phosphorylation. Lot-controlled research material, with traceable CoA confirming identity by mass spectrometry, purity by RP-HPLC, and endotoxin by LAL assay, is a prerequisite for reproducible cross-study comparisons.
For research and laboratory use only. Not for unsupervised human consumption. | Apenas para uso em pesquisa e laboratório. Não para consumo humano não supervisionado. | Solo para uso en investigación y laboratorio. No para consumo humano no supervisado. | Kun til forsknings- og laboratoriebrug. Ikke til ubevåget humant forbrug. | Réservé à la recherche et à l'usage en laboratoire. Ne pas utiliser sans supervision à des fins de consommation humaine. | Nur für Forschungs- und Laborzwecke. Nicht für den unkontrollierten menschlichen Gebrauch. | Solo per uso in ricerca e laboratorio. Non per consumo umano non supervisionato.